Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (80- ). 2006;314(5796):130–3. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.1134108. [Cited 2019 Jun 3.

Article  CAS  Google Scholar 

Amador-Ortiz C, Lin W-L, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s Disease. Ann Neurol. 2007;61(5):435–45. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2677204/pdf/nihms-43267.pdf. [Cited 2017 Dec 7].

Article  PubMed  PubMed Central  CAS  Google Scholar 

Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol. 2014;127(6):811–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24659241. [Cited 2018 Dec 13].

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tomé SO, Vandenberghe R, Ospitalieri S, Van Schoor E, Tousseyn T, Otto M, et al. Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes. Acta Neuropathol Commun. 2020;8(61):1–22.

Google Scholar 

Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;0:1–25. Available from: https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awz099/5481202. [Cited 2019 May 15].

Google Scholar 

Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathologica. 2015;127(6):811–24.

Article  Google Scholar 

Nelson PT, Brayne C, Flanagan ME, Abner EL, Agrawal S, Attems J, et al. Frequency of LATE neuropathologic change across the spectrum of Alzheimer’s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. 2022;144:27–44. https://doi.org/10.1007/s00401-022-02444-1.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Latimer CS, Liachko NF. Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease. GeroScience Press. 2021;43(4):1627–34. https://doi.org/10.1007/s11357-021-00407-0.

Article  CAS  Google Scholar 

Chornenkyy Y, Fardo DW, Nelson PT. Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. Lab Investig. 2019;1. Available from: http://www.nature.com/articles/s41374-019-0196-y. [Cited 2019 Feb 13].

Koper MJ, Tomé SO, Gawor K, Belet A, Van Schoor E, Schaeverbeke J, et al. LATE-NC aggravates GVD-mediated necroptosis in Alzheimer’s disease. Acta Neuropathol Commun. 2022;10(1):128. https://doi.org/10.1186/s40478-022-01432-6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Smith VD, Bachstetter AD, Ighodaro E, Roberts K, Abner EL, Fardo DW, et al. Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi. Brain Pathol. 2018;28(2):264–73. Available from: http://doi.wiley.com/10.1111/bpa.12505. [Cited 2020 Jan 19].

Article  PubMed  CAS  Google Scholar 

Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181–93. Available from: https://academic.oup.com/brain/article/141/7/2181/5033683. [Cited 2018 Aug 16].

Article  PubMed  PubMed Central  Google Scholar 

Wennberg AM, Tosakulwong N, Lesnick TG, Murray ME, Whitwell JL, Liesinger AM, et al. Association of apolipoprotein E ε4 with transactive response DNA-binding protein 43. JAMA Neurol. 2018;75(11):1347. Available from: http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2018.3139. [Cited 2018 Nov 15].

Article  PubMed  PubMed Central  Google Scholar 

Dugan AJ, Nelson PT, Katsumata Y, Shade LM, Boehme KL, Teylan MA, et al. Analysis of genes (TMEM106B, GRN, ABCC9, KCNMB2, and APOE) implicated in risk for LATE-NC and hippocampal sclerosis provides pathogenetic insights: a retrospective genetic association study. Acta Neuropathol Commun. 2021;9(1):152. Available from: http://creativecommons.org/licenses/by/4.0/.TheCreativeCommonsPublicDomainDedicationwaiver. [Cited 2021 Sep 17].

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tomé SO, Gomes L, Li X, Vandenberghe R, Tousseyn T, Thal DR. TDP-43 interacts with pathological τ protein in Alzheimer’s disease. Acta Neuropathol. 2021;141:795–9. https://doi.org/10.1007/s00401-021-02295-2. ([Cited 2021 Apr 2]).

Article  PubMed  CAS  Google Scholar 

Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, et al. Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284–94. Available from: http://www.sciencedirect.com/science/article/pii/S000689930702224X?via%3Dihub. [Cited 2017 Nov 13].

Article  PubMed  CAS  Google Scholar 

Davis SA, Ann Gan K, Dowell JA, Cairns NJ, Gitcho MA. TDP-43 expression influences amyloidβ plaque deposition and tau aggregation. 2017; Available from: https://ac.els-cdn.com/S0969996117300864/1-s2.0-S0969996117300864-main.pdf?_tid=2d283a90-f313-4079-8e3e-b4e84700609c&acdnat=1520243281_1828dad28cff739e94be695a5eb668d0. [Cited 2017 Nov 15].

Latimer CS, Stair JG, Hincks JC, Currey HN, Bird TD, Keene CD, et al. TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic C. elegans. Dis Model Mech. 2022;15(4) Available from: https://journals.biologists.com/dmm/article/doi/10.1242/dmm.049323/274431/TDP-43-promotes-tau-accumulation-and-selective. [cited 2022 Feb 22].

Prasad A, Sivalingam V, Bharathi V, Girdhar A, Patel BK. The amyloidogenicity of a C-terminal region of TDP-43 implicated in Amyotrophic Lateral Sclerosis can be affected by anions, acetylation and homodimerization. Biochimie. 2018 May; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0300908418301263. [Cited 2018 May 14].

Smethurst P, Newcombe J, Troakes C, Simone R, Chen Y-R, Patani R, et al. In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol Dis. 2016;96:236–47. Available from: http://creativecommons.org/licenses/by/4.0/. [Cited 2017 Dec 13].

Article  PubMed  PubMed Central  CAS  Google Scholar 

Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23686809. [Cited 2017 Dec 20].

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ding X, Xiang Z, Qin C, Chen Y, Tian H, Meng L, et al. Spreading of TDP-43 pathology via pyramidal tract induces ALS-like phenotypes in TDP-43 transgenic mice. Acta Neuropathol Commun. 2021;9(1):1–17. https://doi.org/10.1186/s40478-020-01112-3. ([Cited 2021 Jun 22]).

Article  CAS  Google Scholar 

Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol. 2014;127(3):423–39. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24407427. [Cited 2017 Dec 20].

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bocchetta M, del Mar Iglesias Espinosa M, Lashley T, Warren JD, Rohrer JD. In vivo staging of frontotemporal lobar degeneration TDP-43 type C pathology. Alzheimer’s Res Ther. 2020;12(34). https://doi.org/10.1186/s13195-020-00600-x

Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, et al. Updated TDP-43 in Alzheimer’s disease staging scheme. Acta Neuropathol. 2016;131(4):571–85.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Nadl Acad Sci USA. 2014; Available from: www.pnas.org/cgi/doi/https://doi.org/10.1073/pnas.1411649111.[Cited 2021 Feb 11].

Ferrer I, García MA, Carmona M, Andrés-Benito P, Torrejón-Escribano B, Garcia-Esparcia P, et al. Involvement of oligodendrocytes in tau seeding and spreading in tauopathies. Front Aging Neurosci. 2019;11(1):112. Available from: www.frontiersin.org. [Cited 2021 Jun 11].

Article  PubMed  PubMed Central  CAS  Google Scholar 

Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun. 2018;9(1). Available from: www.nature.com/naturecommunications. [Cited 2018 Oct 16].

Fang Y-S, Tsai K-J, Chang Y-J, Kao P, Woods R, Kuo P-H, et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat Commun. 2014;5(1):4824. Available from: https://www.nature.com/articles/ncomms5824.pdf. [Cited 2017 Nov 13].

Article  PubMed  CAS  Google Scholar 

Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111–3. Available from: https://link.springer.com/content/pdf/10.1007%2Fs00401-011-0845-8.pdf. [Cited 2019 Jan 25].

Article  PubMed  PubMed Central  Google Scholar 

Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, Zanette M, et al. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun. 2016;4(1):130. https://doi.org/10.1186/s40478-016-0399-z.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Thal DR, Rub U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791–800. Available from: http://www.neurology.org/cgi/doi/10.1212/WNL.58.12.1791.

Article  PubMed  Google Scholar 

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389–404. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906709/pdf/401_2006_Article_127.pdf. [Cited 2019 Jun 18].

Article  PubMed  PubMed Central  Google Scholar 

Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22265587. [Cited 2018 Jan 3].

Article  PubMed  PubMed Central  Google Scholar 

Nelson PT, Lee EB, Cykowski MD, Alafuzoff I, Arfanakis K, Attems J, et al. LATE-NC staging in routine neuropathologic diagnosis : an update. Acta Neuropathol. 2023;145(2):159–73. https://doi.org/10.1007/s00401-022-02524-2.

Article  PubMed  Google Scholar 

Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8232972. [Cited 2019 Jan 28].

Article  PubMed